Skip to main content
Erschienen in: Current Rheumatology Reports 7/2016

01.07.2016 | Pediatric Rheumatology (S Ozen, Section Editor)

Biologics in Pediatric Rheumatology: Quo Vadis?

verfasst von: Yonit Sterba, Norman Ilowite

Erschienen in: Current Rheumatology Reports | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.
Literatur
2.
Zurück zum Zitat Mangge H, Kenzian H, Gallistl S. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum. 1995;38(2):211–20.CrossRefPubMed Mangge H, Kenzian H, Gallistl S. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum. 1995;38(2):211–20.CrossRefPubMed
5.•
Zurück zum Zitat Guzman J, Kiem O, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74(10):1854–60. doi:10.1136/annrheumdis-2014-205372. This is one of the few articles that discusses outcomes in the era of DMARDs.CrossRefPubMed Guzman J, Kiem O, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74(10):1854–60. doi:10.​1136/​annrheumdis-2014-205372. This is one of the few articles that discusses outcomes in the era of DMARDs.CrossRefPubMed
6.
8.
Zurück zum Zitat Otten MH, Anink J, Prince FH, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national arthritis and biologics in children register. Ann Rheum Dis. 2015;74(7):1379–86. doi:10.1136/annrheumdis-2013-204641.CrossRefPubMed Otten MH, Anink J, Prince FH, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national arthritis and biologics in children register. Ann Rheum Dis. 2015;74(7):1379–86. doi:10.​1136/​annrheumdis-2013-204641.CrossRefPubMed
9.
Zurück zum Zitat Prince FHM, Geerdink LM, Borsboom GJJM, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69(01):138–42. doi:10.1136/ard.2009.111260.CrossRefPubMed Prince FHM, Geerdink LM, Borsboom GJJM, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69(01):138–42. doi:10.​1136/​ard.​2009.​111260.CrossRefPubMed
11.
Zurück zum Zitat Nicolino R, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–106. doi:10.1002/art.22838.CrossRef Nicolino R, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–106. doi:10.​1002/​art.​22838.CrossRef
12.••
Zurück zum Zitat Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20. doi:10.1056/NEJMoa0706290. Initial study showing efficacy of Adalimumab.CrossRefPubMed Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20. doi:10.​1056/​NEJMoa0706290. Initial study showing efficacy of Adalimumab.CrossRefPubMed
13.
Zurück zum Zitat García-De-Vicuña C, Díaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm. 2013;2013:1–6. doi:10.1155/2013/560632.CrossRef García-De-Vicuña C, Díaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm. 2013;2013:1–6. doi:10.​1155/​2013/​560632.CrossRef
14.
Zurück zum Zitat Gabriele S, Taddio A, Cattalini M, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol. 2013;11(1):16. doi:10.1186/1546-0096-11-16.CrossRef Gabriele S, Taddio A, Cattalini M, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol. 2013;11(1):16. doi:10.​1186/​1546-0096-11-16.CrossRef
15.•
Zurück zum Zitat Brunner, Hermine N, Ruperto N, Tzaribachev G, et al. A148: A multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum. 2014;66:S191–92. doi:10.1002/art.38569. First golimumab trial in pediatric rheumatology.CrossRef Brunner, Hermine N, Ruperto N, Tzaribachev G, et al. A148: A multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum. 2014;66:S191–92. doi:10.​1002/​art.​38569. First golimumab trial in pediatric rheumatology.CrossRef
18.•
Zurück zum Zitat Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747–54. doi:10.1136/ard.2010.134254. Initial anakinra trial in SJIA.CrossRefPubMed Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747–54. doi:10.​1136/​ard.​2010.​134254. Initial anakinra trial in SJIA.CrossRefPubMed
19.
Zurück zum Zitat Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–55. doi:10.1002/art.30128.CrossRefPubMed Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–55. doi:10.​1002/​art.​30128.CrossRefPubMed
21.••
Zurück zum Zitat Nicolino R, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–406. doi:10.1056/NEJMoa1205099. This articles includes data from the two canakinumab studies that lead to its FDA approval for SJIA.CrossRef Nicolino R, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–406. doi:10.​1056/​NEJMoa1205099. This articles includes data from the two canakinumab studies that lead to its FDA approval for SJIA.CrossRef
22.
Zurück zum Zitat Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis: rilonacept for systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486–96. doi:10.1002/art.38042.CrossRefPubMed Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis: rilonacept for systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486–96. doi:10.​1002/​art.​38042.CrossRefPubMed
23.
Zurück zum Zitat Ilowite NT, Kristi P, Yuliya L, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis: rilonacept in the treatment of systemic JIA. Arthritis Rheumatol. 2014;66(9):2570–9. doi:10.1002/art.38699.CrossRefPubMedPubMedCentral Ilowite NT, Kristi P, Yuliya L, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis: rilonacept in the treatment of systemic JIA. Arthritis Rheumatol. 2014;66(9):2570–9. doi:10.​1002/​art.​38699.CrossRefPubMedPubMedCentral
25.••
Zurück zum Zitat Brunner HI, Nicolino R, Zbigniew Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110–7. doi:10.1136/annrheumdis-2014-205351. Newest data to support use of tocilizumab in polyarticular course JIA.CrossRefPubMed Brunner HI, Nicolino R, Zbigniew Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110–7. doi:10.​1136/​annrheumdis-2014-205351. Newest data to support use of tocilizumab in polyarticular course JIA.CrossRefPubMed
26.
Zurück zum Zitat Kavanaugh A, Lluís P, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67(12):1739–49. doi:10.1002/acr.22645.CrossRef Kavanaugh A, Lluís P, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67(12):1739–49. doi:10.​1002/​acr.​22645.CrossRef
27.
Zurück zum Zitat McInnes IB, Arthur K, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet (London, England). 2013;382(9894):780–9. doi:10.1016/S0140-6736(13)60594-2.CrossRef McInnes IB, Arthur K, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet (London, England). 2013;382(9894):780–9. doi:10.​1016/​S0140-6736(13)60594-2.CrossRef
28.
Zurück zum Zitat Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional Non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheumatic Dis. 2014;73(6):990–9. doi:10.1136/annrheumdis-2013-204655.CrossRef Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional Non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheumatic Dis. 2014;73(6):990–9. doi:10.​1136/​annrheumdis-2013-204655.CrossRef
29.
Zurück zum Zitat Poddubnyy D, Hermann K-GA, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23. doi:10.1136/annrheumdis-2013-204248.CrossRefPubMed Poddubnyy D, Hermann K-GA, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23. doi:10.​1136/​annrheumdis-2013-204248.CrossRefPubMed
30.
Zurück zum Zitat Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(9):1163–72. doi:10.1007/s10067-011-1720-7.CrossRefPubMed Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(9):1163–72. doi:10.​1007/​s10067-011-1720-7.CrossRefPubMed
31.•
Zurück zum Zitat Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142–50. doi:10.1212/WNL.0000000000000570. This is a retrospective study showing better outcomes in patients with autoinflammatory brain disease treated with rituximab.CrossRefPubMedPubMedCentral Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142–50. doi:10.​1212/​WNL.​0000000000000570​. This is a retrospective study showing better outcomes in patients with autoinflammatory brain disease treated with rituximab.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Baird EM, Lehman TJA, Worgall S. Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report. Pediatric Rheumatol. 2011;9(1):33. doi:10.1186/1546-0096-9-33.CrossRef Baird EM, Lehman TJA, Worgall S. Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report. Pediatric Rheumatol. 2011;9(1):33. doi:10.​1186/​1546-0096-9-33.CrossRef
33.•
Zurück zum Zitat Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatric Rheumatol. 2014;12(1):3. doi:10.1186/1546-0096-12-3. This articles provides an alternative and innovative approach in difficult to treat SLE patients.CrossRef Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatric Rheumatol. 2014;12(1):3. doi:10.​1186/​1546-0096-12-3. This articles provides an alternative and innovative approach in difficult to treat SLE patients.CrossRef
35.
Zurück zum Zitat Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab Registry. J Rheumatol. 2011;38(7):1436–40. doi:10.3899/jrheum.101321.CrossRefPubMed Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab Registry. J Rheumatol. 2011;38(7):1436–40. doi:10.​3899/​jrheum.​101321.CrossRefPubMed
36.
40.
Zurück zum Zitat Moncrieffe H, Ursu S, Holzinger D, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford, England). 2013;52(8):1467–76. doi:10.1093/rheumatology/ket152.CrossRef Moncrieffe H, Ursu S, Holzinger D, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford, England). 2013;52(8):1467–76. doi:10.​1093/​rheumatology/​ket152.CrossRef
Metadaten
Titel
Biologics in Pediatric Rheumatology: Quo Vadis?
verfasst von
Yonit Sterba
Norman Ilowite
Publikationsdatum
01.07.2016
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 7/2016
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-016-0593-9

Weitere Artikel der Ausgabe 7/2016

Current Rheumatology Reports 7/2016 Zur Ausgabe

Chronic Pain (R Staud, Section Editor)

Alexithymia in Chronic Pain Disorders

Vasculitis (LR Espinoza, Section Editor)

Biological Therapy-Induced Systemic Vasculitis

Crystal Arthritis (MH Pillinger and SK Samuels, Section Editors)

Gout Classification Criteria: Update and Implications

Osteoarthritis (MB Goldring, Section Editor)

The Role of Sirtuins in Cartilage Homeostasis and Osteoarthritis

Systemic Lupus Erythematosus (A Saxena, Guest Section Editor)

Update on Biologic Therapies for Systemic Lupus Erythematosus

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.